Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Lantern Pharma ( (LTRN) ).
Lantern Pharma Inc.’s Board of Directors has approved an amendment to the employment agreement for Kishor G. Bhatia, the Chief Scientific Officer. The amendment extends the agreement’s term to January 15, 2026, adjusts his working hours to 24 per week, and sets his annual base salary at $189,600, effective from the first pay period in January 2025.
More about Lantern Pharma
YTD Price Performance: 18.79%
Average Trading Volume: 64,534
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $42.28M
Learn more about LTRN stock on TipRanks’ Stock Analysis page.
